Literature DB >> 7532038

Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors.

R Agarwal1, S Doren, B Hicks, C E Dunbar.   

Abstract

Long-term culture of marrow from patients with chronic myelogenous leukemia (CML) has been reported to favor the outgrowth of bcr/abl- progenitor cells in some patients. We examined the effect of the presence of soluble or transmembrane forms of stem cell factor (SCF) in long-term cultures of CML marrow. CD34-enriched cells from CML patients in advanced chronic phase or accelerated phase were plated on immortalized fetal liver stromal cells from homozygous SCF-deficient SI/SI mice (SI/SI4) with or without the addition of soluble human SCF, SI/SI4 cells expressing high levels of the transmembrane form of human SCF (SI/SIh220), or primary human allogeneic stroma. Cells were removed from cultures and plated weekly in colony assays. The clonagenic cell output from cultures completely lacking SCF was lower over the first 2 to 3 weeks, but by 5 weeks was similar to the clonagenic cell output from the other culture conditions. Analysis of bcr/abl transcripts from individual colonies showed a lower percentage of malignant progenitors present in long-term cultures completely deficient in SCF than under the other culture conditions, particularly compared with primary human stroma-containing long-term cultures. SCF may specifically favor malignant versus benign progenitor cells present in the marrow of CML patients, and an abnormal proliferative response to SCF in very primitive cells may be an underlying defect in the pathophysiology of this disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532038

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Authors:  Amie S Corbin; Thomas O'Hare; Zhimin Gu; Ira L Kraft; Anna M Eiring; Jamshid S Khorashad; Anthony D Pomicter; Tian Y Zhang; Christopher A Eide; Paul W Manley; Jorge E Cortes; Brian J Druker; Michael W Deininger
Journal:  Cancer Res       Date:  2013-07-25       Impact factor: 12.701

2.  Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.

Authors:  Bipin N Savani; Katayoun Rezvani; Stephan Mielke; Aldemar Montero; Roger Kurlander; Charles S Carter; Susan Leitman; Elizabeth J Read; Richard Childs; A John Barrett
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

3.  Blast colony-forming cell binding from CML bone marrow, or blood, on stromal layers pretreated with G-CSF or SCF.

Authors:  J Gidáli; E László; G Halm; I Fehér
Journal:  Cell Prolif       Date:  2002-02       Impact factor: 6.831

4.  An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture.

Authors:  J J Cornelissen; R E Ploemacher; B W Wognum; A Borsboom; H C Kluin-Nelemans; A Hagemeijer; B Löwenberg
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

5.  Clinical and biological predictors of outcome following relapse of CML post-allo-SCT.

Authors:  Natasha A Jain; Sawa Ito; Xin Tian; Roger Kurlander; Minoo Battiwalla; Kit Lu; Bipin N Savani; Vera Malkovska; Katayoun Rezvani; Robert Q Le; Aarthi Shenoy; Christopher S Hourigan; Keyvan Keyvanfar; Eleftheria Koklanaris; Jeanine Superata; Pawel Muranski; A John Barrett; Agnes S M Yong
Journal:  Bone Marrow Transplant       Date:  2014-11-10       Impact factor: 5.483

6.  The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.

Authors:  H Zhan; C H S Lin; Y Segal; K Kaushansky
Journal:  Leukemia       Date:  2017-07-24       Impact factor: 11.528

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.